PRIMARY OBJECTIVE(S):~• To determine the safety and maximum tolerated dose (MTD) of the triple combination of infigratinib with bevacizumab and atezolizumab in patients with FGFR-altered metastatic CCA.~SECONDARY OBJECTIVE(S):~To determine the overall response rate (ORR), as assessed by the treating Investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.~To evaluate the duration of response in subjects with best overall response of complete response (CR) or partial response (PR).~To evaluate PFS defined as the time from the start of study treatment to disease progression or death, whichever occurs first.~To evaluate the duration of OS defined as the time from the start of study treatment to death from any cause.~To evaluate the clinical benefit rate defined as the proportion of subjects with best overall response of CR, PR, or stable disease~EXPLORATORY OBJECTIVE:~• To examine the change of the immune microenvironment with this treatment combination in tumor and blood samplesusing a validated immune biomarker panel and liquid biopsy (end-of-treatment genomic markers using cfDNA analysis) to study resistance to infigratinib and identify response markers from trial medications.
To find the highest tolerable dose of infigratinib that can be given in combination with bevacizumab and atezolizumab to patients with advanced/metastatic CCA with a FGFR2 mutation.